Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 151Leukemia 67Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Leukemia, Myelomonocytic, Acute 26Leukemia, Monocytic, Acute 26Myelodysplastic Syndromes 24Leukemia, Erythroblastic, Acute 23Leukemia, Megakaryoblastic, Acute 22Congenital Abnormalities 21Leukemia, Promyelocytic, Acute 13Leukemia, Myelomonocytic, Chronic 12Anemia, Refractory, with Excess of Blasts 12Recurrence 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Myeloproliferative Disorders 7Leukemia, Myeloid, Chronic-Phase 7Leukemia, Eosinophilic, Acute 7Leukemia, Biphenotypic, Acute 7Leukemia, Basophilic, Acute 6Blast Crisis 6Neoplasm, Residual 4Neutropenia 3Lymphoma 3Leukemia, Myeloid, Accelerated Phase 3Leukemia, Myeloid 3Neoplasms 2Myelodysplastic-Myeloproliferative Diseases 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, T-Cell 2

Interventions

venetoclax 27Cyclophosphamide 18Azacitidine 13fludarabine 12ibrutinib 10Busulfan 10fludarabine phosphate 9Rituximab 8Mycophenolic Acid 8Methotrexate 8Cytarabine 8Whole-Body Irradiation 7Peripheral Blood Stem Cell Transplantation 7Clofarabine 7Therapeutics 6Melphalan 6Antilymphocyte Serum 6obinutuzumab 5Tacrolimus 5Surveys and Questionnaires 5Stem Cell Transplantation 5Mesna 5Exercise 5Cyclosporine 5vosaroxin 4trametinib 4thymoglobulin 4ruxolitinib 4ponatinib 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Idarubicin × Other hematologic neoplasm × Clear all
NCT02834390 2025-03-05

Study of Quizartinib in Japanese Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Daiichi Sankyo

Phase 1 Completed
7 enrolled 16 charts
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

NCT01035502 2013-09-27

A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia

Clavis Pharma

Phase 2 Completed
51 enrolled
Other hematologic neoplasm

Neoplasms, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡